Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




Cell Genesys, Inc. (CEGE) – Ceregene Inc. Secures $5.4 Million in Funding for Phase II Studies

QualityStocks (November 4th, 2008) Writes:

Ceregene Inc. concentrates on the delivery of nervous system growth factors to treat neurodegenerative disorders using gene delivery. Specifically, the company created CERE-110 for the treatment of Alzheimer’s disease, which affects millions of people in the United States.

The company today announced the University of California, San Diego, has received a $5.4 million grant from the National Institute of Aging at the National Institutes of Health to support Ceregene’s phase II clinical study of CERE-100.

“We are pleased to be involved in evaluating CERE-110 which we believe may be a promising therapy for Alzheimer’s disease,” Paul Aisen, M.D., principal investigator of the planned phase 2 trial and director of the Alzheimer’s Disease Cooperative Study at University of California, San Diego, stated in a press release. “Over five million people in the U.S. are currently living with Alzheimer’s disease — a disease which is devastating to patients and their families —

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.